Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 422

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

A New Model of Patient Tumor-Derived Breast Cancer Xenografts for Preclinical Assays

Marangoni, Elisabetta, Vincent-Salomon, Anne, Auger, Nathalie, Degeorges, Armelle, Assayag, Franck, de Cremoux, Patricia, de Plater, Ludmilla, Guyader, Charlotte, De Pinieux, Gonzague, Judde, Jean-Gabriel, Rebucci, Magali, Tran-Perennou, Carine, Sastre-Garau, Xavier, Sigal-Zafrani, Brigitte, Delattre, Olivier, Diéras, Véronique, Poupon, Marie-France·2007·Clinical Cancer Research

Abstract

Purpose: To establish a panel of human breast cancer (HBC) xenografts in immunodeficient mice suitable for pharmacologic preclinical assays. Experimental Design: 200 samples of HBCs were grafted into Swiss nude mice. Twenty-five transplantable xenografts were established (12.5%). Their characterization included histology, p53 status, genetic analysis by array comparative genomic hybridization, gene expression by Western blotting, and quantitative reverse transcription-PCR. Biological profiles of nine xenografts were compared with those of the corresponding patient's tumor. Chemosensitivities of 17 xenografts to a combination of Adriamycin and cyclophosphamide (AC), docetaxel, trastuzumab, and Degarelix were evaluated. Results: Almost all patient tumors established as xenografts displayed an aggressive phenotype, i.e., high-grade, triple-negative status. The histology of the xenografts recapitulated the features of the original tumors. Mutation of p53 and inactivation of Rb and PTEN proteins were found in 83%, 30%, and 42% of HBC xenografts, respectively. Two HBCx had an ERBB2 (HER2) amplification. Large variations were observed in the expression of HER family receptors and in genomic profiles. Genomic alterations were close to those of original samples in paired tumors. Three xenografts formed lung metastases. A total of 15 of the 17 HBCx (88%) responded to AC, and 8 (47%) responded to docetaxel. One ERBB2-amplified xenograft responded to trastuzumab, whereas the other did not. The drug response of HBC xenografts was concordant with that of the patient's tumor in five of seven analyzable cases. Conclusions: This panel of breast cancer xenografts includes 15 triple-negative, one ER positive and 2 ERBB2 positive. This panel represents a useful preclinical tool for testing new agents and protocols and for further exploration of the biological basis of drug responses.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-07-0078

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Cited by

See all 422

Metadata

Authors
Marangoni, E., Vincent-Salomon, A., Auger, N., Degeorges, A., Assayag, F., de Cremoux, P., de Plater, L., Guyader, C., De Pinieux, G., Judde, J.-G., Rebucci, M., Tran-Perennou, C., Sastre-Garau, X., Sigal-Zafrani, B., Delattre, O., Diéras, V., & Poupon, M.-F.
Venue
Clinical Cancer Research
Published
2007-07-01
Volume
13
Issue
13
Pages
3989-3998
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2103875073
Cited by
422
References
22
FWCI
2.14
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A New Model of Patient Tumor-Derived Breast Cancer Xenografts for Preclinical Assays. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-07-0078
The paper
Marangoni, E., Vincent-Salomon, A., Auger, N., Degeorges, A., Assayag, F., de Cremoux, P., de Plater, L., Guyader, C., De Pinieux, G., Judde, J.-G., Rebucci, M., Tran-Perennou, C., Sastre-Garau, X., Sigal-Zafrani, B., Delattre, O., Diéras, V., & Poupon, M.-F. (2007). A New Model of Patient Tumor-Derived Breast Cancer Xenografts for Preclinical Assays. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-07-0078

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.